APA (7th ed.) Citation

Glicksman, R., Kishan, A., Katz, A., Mantz, C., Collins, S., Fuller, D., . . . Loblaw, A. (2022). Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis. Clinical Oncology, 34(1), 36. https://doi.org/10.1016/j.clon.2021.11.004

Chicago Style (17th ed.) Citation

Glicksman, R.M, et al. "Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis." Clinical Oncology 34, no. 1 (2022): 36. https://doi.org/10.1016/j.clon.2021.11.004.

MLA (9th ed.) Citation

Glicksman, R.M, et al. "Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis." Clinical Oncology, vol. 34, no. 1, 2022, p. 36, https://doi.org/10.1016/j.clon.2021.11.004.